Traduction de «swedish » (Français → Néerlandais) :

Swedish Orphan Biovitrum International AB SE-112 76 Stockholm Suède
Swedish Orphan Biovitrum International AB SE-112 76 Stockholm Zweden

Swedish Orphan Biovitrum AB (publ) Strandbergsgatan 49 SE-11276 Stockholm Suède
Swedish Orphan Biovitrum AB (publ) Strandbergsgatan 49 SE-11276 Stockholm Zweden

18. Larsson LG, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabar L, et al. Updated overview of the Swedish Randomized Trials on Breast Cancer Screening with Mammography: age group 40-49 at randomization.
18. Bjurstam N, Bjorneld L, Warwick J, Sala E, Duffy SW, Nystrom L, et al. The Gothenburg Breast Screening Trial.

51. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials.
52. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials.

143. Strandberg EL, Ovhed I, Borgquist L, Wilhelmsson S. The perceived meaning of a (w)holistic view among general practitioners and district nurses in Swedish primary care: a qualitative study.
143. Mello MM, Chandra A, Gawande AA, Studdert DM.

Autres informations relatives à Orfadin: La Commission européenne a délivré une autorisation de mise sur le marché valable dans toute l’Union européenne pour Orfadin à Swedish Orphan International AB, le 21 février 2005.
Overige informatie over Orfadin: De Europese Commissie heeft op 21 februari 2005 een in de hele Europese Unie geldige vergunning voor het in de handel brengen van Orfadin verleend aan Swedish Orphan International AB.

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow up.

Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system.
Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin‐‐results from the Swedish spontaneous adverse drug reaction reporting system.

Titulaire de l'Autorisation de mise sur le marché : Swedish Orphan Biovitrum International AB SE-112 76 Stockholm Suède
Houder van de vergunning voor het in de handel brengen en fabrikant Swedish Orphan Biovitrum International AB SE-112 76 Stockholm Zweden